Our Mission: Reduce Clinical Uncertainty
Current Challenges
Low accuracy in current liquid biopsy tests-meaning low sensitivity and specificity-leads to a high number of false results, including both false positives and false negatives. As a result, many patients receive incorrect diagnoses, which can cause unnecessary anxiety, confusion, and lead to invasive procedures that may not be needed, ultimately driving up healthcare costs.
Even with imaging technologies like mammograms and low-dose CT scans, false results remain a significant issue. These limitations not only impact patient well-being but also contribute to the overuse of invasive follow-up tests and treatments that may not be warranted.
Addressing these challenges requires more accurate, accessible, and equitable diagnostic solutions to ensure that all patients can benefit from early and reliable cancer detection.
The Protein Advantage
Unlike many other technologies that rely on difficult to find and expensive DNA processing, Definitive Diagnostics measures specific cancer-related proteins that are easily detected, cost-effective, and are the body's first indication of cancer.
Most liquid biopsies rely on broad detection and the "likelihood" of possibly a number of cancers that require more testing. We believe in high accuracy for the most prevalent and aggressive cancers.
Achieving Accuracy
Our proprietary technology delivers accurate detection of breast, lung, colorectal, ovarian and pancreatic cancers.
We measure protein and immune biomarkers and have discovered unique patterns for individual cancers.
These patterns do not overlap and as a result, we can determine with 98% Tissue of Origin (ToO) accuracy, which type of cancer is present (when present), and can rule out cancer from mammograms or LD-CATs that generate false results.
The platform measures 16 biomarker parameters present in blood to accurately detect cancer with high precision. Independent assessment of early lab results shows 99% sensitivity across all target cancers (including Stages 0, I detection), 97-99% specificity, and 98% Tissue of Origin.